Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989) has released an update.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. has scheduled a board meeting on October 30, 2024, to review and approve its third-quarter financial results for the period ending September 30, 2024. The outcome of this meeting could provide valuable insights into the company’s performance for interested investors.
For further insights into HK:9989 stock, check out TipRanks’ Stock Analysis page.